THIS IS A NON-COMPETITIVE (NOTICE OF INTENT) COMBINED SYNOPSIS SOLICITATION TO AWARD A CONTRACT OR PURCHASE ORDER WITHOUT PROVIDING FOR FULL OR OPEN COMPETITION (INCLUDING BRAND-NAME).

The National Institute on Drug Abuse (NIDA), Office of Acquisition (OA), on behalf of the National Center for Advancing Translational Sciences (NCATS), intends to negotiate and award a purchase order without providing for full and open competition (including brand-name) to Covance Laboratories Inc., 3301 Kinsman Blvd, Madison, WI  53704-2523.  Covance Laboratories Inc. is performing other pharmacokinetics for this project, and to eliminate any variables and ensure the continuity of data, this pharmacokinetics requirement must also be completed by Covance Laboratories Inc.

DESCRIPTION: (2R,6R)-Hydroxynorketamine (2R,6R-HNK) is currently in phase 1 human clinical trials. NCATS needs to obtain the cerebrospinal fluid (CSF) levels of 2R,6R-HNK in order to determine if the compound is penetrating the blood brain barrier in human subjects.

See attached Request for Quotations, Statement of Work, and other attachments for complete requirement details.